Physician profile
Anh Le
NPI 1922158872
$1,693.56
in general payments reported to CMS, 2019-2025
17 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $121 · 2021: $134 · 2022: $263 · 2023: $130 · 2024: $641 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,016.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $254.03 | 2020-2024 | |
| Sun Pharmaceutical Industries INC. | $208.40 | 2019-2025 | Cequa |
| Glaukos Corporation | $206.27 | 2021-2025 | Idosetr |
| Rxsight INC | $193.55 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $159.39 | 2019-2021 | |
| Abbvie INC. | $137.26 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $125.18 | 2022-2024 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $73.51 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $69.57 | 2020-2022 | |
| Alcon Vision LLC | $58.79 | 2019-2023 | Clareon |
| Dompe US, INC. | $55.15 | 2022-2024 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $52.80 | 2025 | Xdemvy |
| Allergan, INC. | $24.51 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $22.82 | 2022 | |
| Harrow Eye, LLC | $22.37 | 2024 | Vevye |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $15.70 | 2025 | Tyrvaya, Ryzumvi |
| Coopervision INC. | $14.26 | 2025 | Myday Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anh Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.